Discontinued ProductUnfortunately 6-Nitroindazole (Cat. No. 0710) has been withdrawn from sale for commercial reasons.
nNOS inhibitor. Less potent antinociceptive than the 7-nitro analogue (0602), but is equally potent in relaxing smooth muscle independently of its inhibition of NO synthase.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the products' biological activity.
Medhurst et al (1994) NO synthase inhibitors 7- and 6-nitroindazole relax smooth muscle in vitro. Eur.J.Pharmacol. 256 R5 PMID: 7517888
Moore et al (1993) Characterisation of the novel NO synthase inhibitor 7-nitroindazole and related indazoles: antinociceptive and cardiovascular effects. Br.J.Pharmacol. 110 219 PMID: 7693278
View Related Products by Product Action
Keywords: 6-Nitroindazole, supplier, nNOS, nNOS, Tocris Bioscience
Citations for 6-Nitroindazole
Citations are publications that use Tocris products.
Currently there are no citations for 6-Nitroindazole.
Reviews for 6-Nitroindazole
There are currently no reviews for this product. Be the first to review 6-Nitroindazole and earn rewards!
Have you used 6-Nitroindazole?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.